Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Boehringer Ingelheim
Moodys
Merck
Colorcon

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR ILUVIEN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Iluvien

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00770770 ↗ Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina Terminated Alimera Sciences Phase 2 2009-05-01 This study will assess the safety and efficacy of FA Intravitreal Inserts in subjects with macular edema secondary to RVO.
NCT01304706 ↗ Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study Completed Alimera Sciences Phase 3 2011-04-01 This study will assess the safety and utility of the new inserter for the administration of ILUVIEN in subjects with diabetic macular edema.
NCT02359526 ↗ A Pilot Study on the Effect and Safety of IluvienĀ® in Chronic Diabetic Macular Edema Patients Completed Association for Innovation and Biomedical Research on Light and Image Phase 4 2014-10-01 To provide treating physicians with experience with ILUVIEN as well as monitoring its safety (and effectiveness) in a real-life chronic diabetic macular edema (DME) patients judged insufficiently responsive to available therapies.
NCT02424019 ↗ Phase 4 IOP Signals Associated With ILUVIENĀ® Unknown status Alimera Sciences Phase 4 2015-05-06 This study will assess the safety in patients treated with ILUVIEN, with primary focus on IOP.
NCT02472366 ↗ A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIENĀ® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Co Completed Alimera Sciences Phase 4 2014-01-01 A phase 4 trial evaluating the effect and safety of ILUVIEN in chronic DME patients insufficiently responsive to available therapies.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Iluvien

Condition Name

Condition Name for Iluvien
Intervention Trials
Diabetic Macular Edema 5
Diabetes 1
Diabetic Macular Edema (DME) 1
Macular Edema 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Iluvien
Intervention Trials
Macular Edema 8
Edema 7
Retinal Vein Occlusion 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Iluvien

Trials by Country

Trials by Country for Iluvien
Location Trials
United States 44
Puerto Rico 1
Portugal 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Iluvien
Location Trials
Georgia 3
Oklahoma 2
Colorado 2
Florida 2
California 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Iluvien

Clinical Trial Phase

Clinical Trial Phase for Iluvien
Clinical Trial Phase Trials
Phase 4 5
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Iluvien
Clinical Trial Phase Trials
Completed 3
Withdrawn 2
Unknown status 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Iluvien

Sponsor Name

Sponsor Name for Iluvien
Sponsor Trials
Alimera Sciences 5
Association for Innovation and Biomedical Research on Light and Image 1
Johns Hopkins University 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Iluvien
Sponsor Trials
Industry 5
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Colorcon
AstraZeneca
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.